Skip to main content

Day: December 26, 2024

Crown CEO Issues Update Letter to Shareholders

Special Meeting of Stockholders To Approve Reverse Stock Split To Be Held on January 14th at 10:00 a.m. ET LOS ANGELES, Dec. 26, 2024 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading provider of innovative technology infrastructure solutions that benefit communities and the environment, today provided a letter to shareholders from its CEO and Chairman, Doug Croxall. Dear Fellow Shareholders, As 2024 comes to a close, I want to reflect on Crown’s accomplishments this year and share our vision for the year ahead. It has been a transformative year for Crown, as we have evolved into a rapidly growing public conglomerate with three diversified divisions: Smart Windows, Fiber Optics, and Water Solutions. This year, we made significant operational progress, achieving...

Continue reading

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding. “As we continue to look for ways to conserve resources and maximize value for the company, we made the very difficult decision to close the...

Continue reading

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Failure to Complete Initial Business Combination

New York, NY, Dec. 26, 2024 (GLOBE NEWSWIRE) — NorthView Acquisition Corporation (Nasdaq: NVAC) (the “Company”) announced that it has received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that (i) the Staff has determined that the Company’s securities will be delisted from The Nasdaq Stock Market; (ii) trading of the Company’s Common Stock, Rights, and Warrants will be suspended at the opening of business on December 27, 2024; and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing on The Nasdaq Stock Market. Pursuant to Nasdaq Listing Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the...

Continue reading

Solitron Devices, Inc. Announces Fiscal 2025 Third Quarter Bookings of $8 Million

WEST PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) — Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2025 third quarter bookings were in excess of $8 million.   Bookings in the fiscal 2025 third quarter were approximately $8.0 million as compared to approximately $4.8 million in the fiscal 2024 third quarter. Bookings in the first nine months of fiscal 2025 were approximately $11.8 million as compared to approximately $10.6 million in the first nine months of fiscal 2024.   It should be noted that bookings for the first nine months of fiscal 2024 included only one quarter for MEI, whereas bookings for the first nine months of fiscal 2025 included three quarters for MEI. Backlog as of November 30, 2024, was approximately $12.3 million as compared to approximately $13.0 million...

Continue reading

ARMOUR Residential REIT, Inc. Announces Guidance for January 2025 Dividend Rate per Common Share

VERO BEACH, Florida, Dec. 26, 2024 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the January 2025 cash dividend for the Company’s Common Stock of $0.24 per Common share. January 2025 Common Stock Dividend InformationMonth   Dividend   Holder of Record Date   Payment DateJanuary 2025   $0.24   January 15, 2025   January 30, 2025Certain Tax Matters ARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are...

Continue reading

Preferred Bank Announces Dividend Increase

LOS ANGELES, Dec. 26, 2024 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the largest independent commercial banks in California, today reported that the Board of Directors has increased the quarterly cash dividend to $0.75 per share from the previous $0.70 per share, an increase of 7.1%. The dividend is payable on January 23, 2025 to holders of record on January 9, 2025. About Preferred Bank Preferred Bank is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through twelve full-service branch banking offices in the California cities...

Continue reading

$10M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Reno, Nev., Dec. 26, 2024 (GLOBE NEWSWIRE) —  American Battery Technology Company (NASDAQ: ABAT), an integrated critical battery materials company that is commercializing its technologies for both primary battery minerals manufacturing and secondary minerals lithium-ion battery recycling, today announced it has entered into securities purchase agreements with two institutional investors for the purchase and sale of 3,773,586 shares of its common stock and warrants to purchase up to an aggregate of 3,773,586 shares of common stock in a registered direct offering.  The last closing market price was $2.60 per share and this intraday transaction had at a combined offering price of $2.65 per share and accompanying warrant, priced “at-the-market” under Nasdaq rules. The warrants have an exercise price of $2.80 per share, and will be...

Continue reading

2024 Year-End NAIC Designations for STACR REMIC Trust, STACR Trust, and STACR Debt Notes

MCLEAN, Va., Dec. 26, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today published on its website the National Association of Insurance Commissioners (NAIC) 2024 filing year designations for certain STACR REMIC Trust, STACR Trust, and STACR Debt Notes (collectively, “STACR Notes”). Overall, of the 209 reviewed STACR Notes, all have achieved NAIC 1 Designation including all A1, M1 and M2 Notes offered through 2024 STACR transactions. In addition, 10 of the 2024 NAIC 1 Designations are upgrades from their 2023 NAIC 2 Designations. The below table details the upgrades:CUSIP Deal Name 2023 Year-End NAIC Designation 2023 Year-End NAIC Designation Modifier 2024 Year-End NAIC Designation 2024 Year-End NAIC Designation Modifier35564KB57 STACR 2022-HQA2 M2B 2 B 1 E35564KB65 STACR 2022-HQA2 M2 2 A 1 D35564KE62 STACR 2022-HQA3...

Continue reading

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it. AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs. Panelists to include David Rhew (Global Chief Medical Officer and VP of Healthcare, Microsoft), Sean Tunis (Principal, Rubix Health), Peter Ehrhardt (Senior Partner, Simon-Kucher), and Poonam Alaigh...

Continue reading

In France, start of construction of three photovoltaic projects

In France, start of construction of three photovoltaic projects Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energy, launches construction of three new solar power plants in the south of France with a total capacity of 25.1 megawatts The first project involves the construction of a photovoltaic park with a total output of 10.7 megawatts. The project is located on a 15-hectare agricultural wasteland. The choice of a specific technology for the structures supporting the solar panels with trackers1 and the implementation of an appropriate irrigation system will enable farming activities to resume. The other two projects, with capacities of 8.2 megawatts and 6.2 megawatts respectively, are solar farms with fixed structures. In total, the production of the three projects represents the annual electricity...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.